NASDAQ:PAND - Nasdaq -
60.05
+0.13 (+0.22%)
The current stock price of PAND is 60.05 null. In the past month the price decreased by -2.56%.
Pandion Therapeutics Inc. is a biotechnology company. It focuses on developing modular proteins, antibodies and bispecifics for the treatment of autoimmune and inflammatory diseases. Pandion Therapeutics Inc. is based in North Cambridge, United States.
Pandion Therapeutics Inc
134 COOLIDGE AVENUE 2ND FLOOR
WATERTOWN MA 02472
CEO: Rahul Kakkar
Phone: 617-393-5925
The current stock price of PAND is 60.05 null. The price increased by 0.22% in the last trading session.
The exchange symbol of Pandion Therapeutics Inc is PAND and it is listed on the Nasdaq exchange.
PAND stock is listed on the Nasdaq exchange.
Pandion Therapeutics Inc (PAND) has a market capitalization of 1.77B null. This makes PAND a Small Cap stock.
Pandion Therapeutics Inc (PAND) has a support level at 60.02 and a resistance level at 61.64. Check the full technical report for a detailed analysis of PAND support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PAND does not pay a dividend.
Pandion Therapeutics Inc (PAND) will report earnings on 2022-03-11, after the market close.
Pandion Therapeutics Inc (PAND) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.81).
ChartMill assigns a technical rating of 6 / 10 to PAND.
ChartMill assigns a fundamental rating of 1 / 10 to PAND. PAND may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months PAND reported a non-GAAP Earnings per Share(EPS) of -2.8116. The EPS increased by 86.71% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -434.05% | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 73% to PAND. The Buy consensus is the average rating of analysts ratings from 3 analysts.